ARTICLE | Company News
3SBio to market two Taiwan Liposome products in China
March 8, 2019 5:31 PM UTC
3SBio gained exclusive Chinese rights to commercialize two undisclosed liposomal products using Taiwan Liposome's NanoX platform in oncology and infectious disease indications.
Taiwan Liposome Co. Ltd. (TPEx:4152; NASDAQ:TLC) and 3SBio Inc. (HKSE:1530) will together seek Chinese regulatory approval of the products in the near future...